Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT04705025 | Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer(BNT001) | terminated | N/A | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 25, 2023 |
| clinicaltrials |
| NCT02710396 | Genetic Predictors of Benefit to Pembrolizumab | terminated | Phase 2 | 19 | Columbia UniversityOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT02919449 | Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab | terminated | Phase 1 | 2 | Vyriad, Inc.INDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT03927573 | Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker | terminated | Phase 1 | 23 | AvenCell Europe GmbHINDUSTRY | 1 | Jul 10, 2023 | clinicaltrials |
| NCT02584634 | Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) | terminated | Phase 1 / Phase 2 | 43 | PfizerINDUSTRY | 5 | Jul 7, 2023 | clinicaltrials |
| NCT00750698 | A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib | terminated | Phase 2 | 8 | Syndax PharmaceuticalsINDUSTRY | 1 | Jul 6, 2023 | clinicaltrials |
| NCT03805841 | Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions(RAIN) | terminated | Phase 2 | 41 | Rain Oncology IncINDUSTRY | 3 | Jun 28, 2023 | clinicaltrials |
| NCT04381494 | Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.(ON TRAX) | terminated | Phase 4 | 40 | AstraZenecaINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02335944 | Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | terminated | Phase 1 / Phase 2 | 177 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 18, 2023 | clinicaltrials |
| NCT05153408 | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | terminated | Phase 1 | 20 | Blueprint Medicines CorporationINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03509584 | Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients | terminated | Phase 1 | 6 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04372927 | ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy | terminated | Phase 2 | 1 | University of WashingtonOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT03827850 | FGFR Inhibitor in FGFR Dysregulated Cancer(FIND) | terminated | Phase 2 | 22 | Lung Cancer Group CologneOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | terminated | Phase 1 / Phase 2 | 63 | 4D pharma plcINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT03233724 | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | terminated | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | May 31, 2023 | clinicaltrials |
| NCT04849273 | A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC | terminated | Phase 1 | 11 | Turning Point Therapeutics, Inc.INDUSTRY | 3 | May 26, 2023 | clinicaltrials |
| NCT03984019 | Cardiac Changes After Stereotactic Radiotherapy for Early Stage NSCLC Cancer or Lung Metastasis(HALO) | terminated | N/A | 10 | The Netherlands Cancer InstituteOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | 1,333 | SWOG Cancer Research NetworkNETWORK | 2 | May 23, 2023 | clinicaltrials |
| NCT02382406 | Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC | terminated | Phase 1 / Phase 2 | 46 | Nisha Mohindra, MDOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT00227617 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | terminated | Phase 2 / Phase 3 | 36 | University of California, San FranciscoOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03275597 | Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition | terminated | Phase 1 | 17 | University of Wisconsin, MadisonOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT02961283 | Study of ASN003 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 24 | Asana BioSciencesINDUSTRY | 1 | May 9, 2023 | clinicaltrials |
| NCT01912625 | Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | terminated | Phase 1 | 16 | National Cancer Institute (NCI)NIH | 1 | May 6, 2023 | clinicaltrials |
| NCT03488472 | Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain(RAD 1704) | terminated | N/A | 1 | Drexell Hunter BoggsOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT03802058 | Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer | terminated | Phase 2 | 24 | Wuhan UniversityOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT03574194 | Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy | terminated | N/A | 8 | West Virginia UniversityOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05001724 | KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent | terminated | Phase 2 / Phase 3 | 16 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Apr 25, 2023 | clinicaltrials |
| NCT04590781 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 4 | Xencor, Inc.INDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04863248 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)(PRESERVE 4) | terminated | Phase 2 | 10 | G1 Therapeutics, Inc.INDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT03406715 | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) | terminated | Phase 2 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 118 | Calithera Biosciences, IncINDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT01567722 | Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies | terminated | — | 114 | AIDS Malignancy ConsortiumNETWORK | 1 | Mar 16, 2023 | clinicaltrials |
| NCT03030131 | Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer(IONESCO) | terminated | Phase 2 | 50 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT04698681 | NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial | terminated | — | 20 | Calithera Biosciences, IncINDUSTRY | 1 | Mar 13, 2023 | clinicaltrials |
| NCT03138889 | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors(PROPEL) | terminated | Phase 1 / Phase 2 | 162 | Nektar TherapeuticsINDUSTRY | 5 | Mar 10, 2023 | clinicaltrials |
| NCT03838848 | KN046 in Patients With Advanced Non-small Cell Lung Cancer | terminated | Phase 2 | 120 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 2, 2023 | clinicaltrials |
| NCT03713944 | Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 30 | Nasser HannaOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03265080 | A Study of ADXS-NEO Expressing Personalized Tumor Antigens(NEO) | terminated | Phase 1 | 13 | Advaxis, Inc.INDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
| NCT04438902 | Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment | terminated | Phase 2 | 3 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04622072 | XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 | 21 | Sihuan Pharmaceutical Holdings Group Ltd.INDUSTRY | 1 | Feb 17, 2023 | clinicaltrials |
| NCT03707925 | Bronchoscopic Laser Ablation of Peripheral Lung Tumors | terminated | N/A | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02963090 | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | terminated | Phase 2 | 9 | Alliance Foundation Trials, LLC.OTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT03656627 | Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease | terminated | Phase 1 | 7 | Alliance Foundation Trials, LLC.OTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT03663166 | Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT05725343 | A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer(CANAL) | terminated | Phase 3 | 350 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 | 41 | Calithera Biosciences, IncINDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT03599518 | DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | terminated | Phase 1 | 20 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jul 25, 2023source: clinicaltrials